GetTopicDetailResponse(id=ed70e91027a, topicName=維莫非尼, introduction=維莫非尼, content=null, image=null, comments=2, allHits=1303, url=https://h5.medsci.cn/topic?id=79102, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=47745, tagList=[TagDto(tagId=47745, tagName=維莫非尼)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2211946, encodeId=055b2211946bc, content=<a href='/topic/show?id=ed70e91027a' target=_blank style='color:#2F92EE;'>#維莫非尼#</a> <a href='/topic/show?id=b85c115938d9' target=_blank style='color:#2F92EE;'>#BRAF V600突變#</a> <a href='/topic/show?id=7bab1144686a' target=_blank style='color:#2F92EE;'>#妥拉美替尼#</a>, objectTitle=EXP HEMATOL ONCOL：妥拉美替尼 (HL-085) 與維莫非尼聯(lián)合治療BRAF V600突變實體瘤的 I 期臨床試驗, objectType=article, longId=830734, objectId=bc5b830e34bc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240621/1718954446002_92910.png, objectUrl=/article/show_article.do?id=bc5b830e34bc, replyNumber=0, likeNumber=80, createdTime=2024-06-27, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=bc5b830e34bc, moduleTitle=EXP HEMATOL ONCOL：妥拉美替尼 (HL-085) 與維莫非尼聯(lián)合治療BRAF V600突變實體瘤的 I 期臨床試驗, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=bc5b830e34bc)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2045529, encodeId=d07f2045529b8, content=<a href='/topic/show?id=ed70e91027a' target=_blank style='color:#2F92EE;'>#維莫非尼#</a>, objectTitle=Clin Cancer Res: 考比替尼（cobimetinib）+ 維莫非尼（vemurafenib）對比安慰劑+ 維莫非尼（vemurafenib）治療BRAF V600突變陽性轉(zhuǎn)移性黑色素瘤的療效和安全性: coBRIM研究5年長期隨訪結(jié)果, objectType=article, longId=213315, objectId=46ab21331526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46ab21331526, replyNumber=0, likeNumber=69, createdTime=2021-09-30, rootId=0, userName=wangbingxhy, userId=baf586, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46ab21331526, moduleTitle=Clin Cancer Res: 考比替尼（cobimetinib）+ 維莫非尼（vemurafenib）對比安慰劑+ 維莫非尼（vemurafenib）治療BRAF V600突變陽性轉(zhuǎn)移性黑色素瘤的療效和安全性: coBRIM研究5年長期隨訪結(jié)果, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=46ab21331526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2045528, encodeId=b645204552856, content=<a href='/topic/show?id=ed70e91027a' target=_blank style='color:#2F92EE;'>#維莫非尼#</a>, objectTitle=羅氏黑色素瘤新藥「維莫非尼」獲CFDA批準上市, objectType=article, longId=93141, objectId=ee2c931418a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee2c931418a, replyNumber=0, likeNumber=80, createdTime=2017-08-30, rootId=0, userName=wangbingxhy, userId=baf586, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee2c931418a, moduleTitle=羅氏黑色素瘤新藥「維莫非尼」獲CFDA批準上市, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=ee2c931418a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
